Literature DB >> 11295785

Long-duration effect and the postsynaptic compartment: study using a dopamine agonist with a short half-life.

F Stocchi1, L Vacca, A Berardelli, F De Pandis, S Ruggieri.   

Abstract

A possible reason why levodopa induces a sustained, stable motor benefit during the first months to years of therapy may be its long duration of action. This long-duration effect may be due either to a presynaptic storage mechanism or to postsynaptic pharmacodynamic changes. We previously reported that the dopamine agonist ropinirole induced a long-duration response (LDR) in levodopa-naive patients with Parkinson's disease. In this study, we investigated motor responses to the short half-life dopamine agonist lisuride in a group of levodopa naive parkinsonian patients. Once lisuride reached its maximum effect, it was substituted, in randomized order, with placebo. Neither investigators nor patients knew when the active drug was switched to placebo. When patients were switched from lisuride to placebo, their Unified Parkinson's Disease Rating Scale (UPDRS) motor scores and tapping test and screw scores declined to baseline values within a mean 9.0 +/- 1.9 days. The results confirmed that, like ropinirole and levodopa, the short-acting dopamine agonist lisuride induces a long-duration response, probably due to postsynaptic changes. Copyright 2001 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11295785     DOI: 10.1002/mds.1070

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  10 in total

1.  Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

Review 2.  Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease.

Authors:  D James Surmeier; Glenda M Halliday; Tanya Simuni
Journal:  Exp Neurol       Date:  2017-08-02       Impact factor: 5.330

3.  End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease.

Authors:  Astrid Thomas; Laura Bonanni; Angelo Di Iorio; Sara Varanese; Francesca Anzellotti; Anna D'Andreagiovanni; Fabrizio Stocchi; Marco Onofrj
Journal:  J Neurol       Date:  2006-12       Impact factor: 4.849

Review 4.  The missing, the short, and the long: Levodopa responses and dopamine actions.

Authors:  Roger L Albin; Daniel K Leventhal
Journal:  Ann Neurol       Date:  2017-06-05       Impact factor: 10.422

Review 5.  The role of neuroplasticity in dopaminergic therapy for Parkinson disease.

Authors:  Xiaoxi Zhuang; Pietro Mazzoni; Un Jung Kang
Journal:  Nat Rev Neurol       Date:  2013-04-16       Impact factor: 42.937

Review 6.  Adaptive changes in striatal projection neurons explain the long duration response and the emergence of dyskinesias in patients with Parkinson's disease.

Authors:  Björn Falkenburger; Theodoros Kalliakoudas; Heinz Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2022-05-10       Impact factor: 3.850

7.  A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III).

Authors:  Kevin M Biglan; David Oakes; Anthony E Lang; Robert A Hauser; Karen Hodgeman; Brittany Greco; Jillian Lowell; Rebecca Rockhill; Ira Shoulson; Charles Venuto; Diony Young; Tanya Simuni
Journal:  Ann Clin Transl Neurol       Date:  2017-05-09       Impact factor: 4.511

Review 8.  Parkinson's disease and translational research.

Authors:  Elisabeth Dinter; Theodora Saridaki; Leonie Diederichs; Heinz Reichmann; Björn H Falkenburger
Journal:  Transl Neurodegener       Date:  2020-12-01       Impact factor: 8.014

Review 9.  Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?

Authors:  Silvia Rota; Daniele Urso; Daniel J van Wamelen; Valentina Leta; Iro Boura; Per Odin; Alberto J Espay; Peter Jenner; K Ray Chaudhuri
Journal:  Transl Neurodegener       Date:  2022-10-13       Impact factor: 9.883

10.  Dopamine agonist treatment increases sensitivity to gamble outcomes in the hippocampus in de novo Parkinson's disease.

Authors:  Joyce P M van der Vegt; Oliver J Hulme; Kristoffer H Madsen; Carsten Buhmann; Bastiaan R Bloem; Alexander Münchau; Rick C Helmich; Hartwig R Siebner
Journal:  Neuroimage Clin       Date:  2020-07-25       Impact factor: 4.881

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.